In drug discovery research it is vital to investigate the way a potential drug candidate molecule is absorbed, distributed, metabolized and excreted (ADME) in order to prevent a lot of time and money being spent on pharmaceutical compounds which are toxic to humans. ADME profiling looks at the pharmacokinetics of new pharmaceutical compounds by looking at what the body does to the drug and one of the important aspects is drug metabolism. Pharmacokinetics studies investigate ADME because these four criteria all influence the drug levels and kinetics of drug exposure to the tissues and hence influence the performance and pharmacological activity of the pharmaceutical compound as a drug. Drug metabolism and pharmacokinetics also known as DMPK looks at how the compound is broken down by investigating the formation of metabolites in the liver and the influence of cytochrome P450 enzymes which are responsible for most small-molecule drug metabolism. NoAb BioDiscoveries is a cutting edge provider of specialized and proprietary research services that help to shape and optimize the drug discovery process. These services include in vitro ADME assays, in vivo pharmacokinetics studies, bioanalysis and gene expression assays.
In vitro ADME profiling at NoAb BioDiscoveries is of high quality and high efficiency due to the use of high throughput screening which enables important information to be generated at a rapid pace. The information generated on drug metabolism and pharmacokinetics can be used to explain any toxicological or efficacy problems as well as to aid planning of drug-drug interactions and phase I clinical trials in humans. Drug metabolism and pharmacokinetics data is generated from assays such as cell permeability, plasma protein binding, cytochrome P450 subtypes inhibition, metabolic stability in hepatocytes, metabolic stability in liver subcellular fractions, plasma stability and cytotoxicity. Detailed information on each of these assays is available at www.noabbiodiscoveries.com.
NoAb BioDiscoveries generates drug metabolism and pharmacokinetics data that is accurate and reliable through superior scientific procedures to help select and prioritize leads. The results of the in vitro assays combined with preliminary toxicity evaluations assist in developing the hits from high throughput screening into leads. These leads can then be optimized into promising drug candidates ensuring your success in identifying the best candidates for further pre-clinical and clinical development. NoAb BioDiscoveries is committed to delivering innovative tools and technologies that help to accelerate the drug discovery process, reducing costs and maximizing success and with the advanced research tools continuously developed at the research facility, the organization has managed to consistently accomplish this goal. These advanced tools allow better characterization of the drug metabolism and pharmacokinetics of new drug candidates resulting in the optimization of the selection of the viable clinical candidates.
As a result of the cutting edge services such as drug metabolism and pharmacokinetics studies and gene expression profiling, NoAb BioDiscoveries delivers premier drug discovery services to its clients ensuring success and accelerated timelines in producing optimal and viable clinical candidates. The expert scientists design the best strategies and protocols to suit any drug discovery need and perform standard and specialized procedures according to customer specifications. With the complete range of specialized and proprietary research services provided by NoAb BioDiscoveries, you can be assured that you will get quality, efficient and timely service that will reduce costs and the time required to market a new drug!
